Characteristics of Stress Sensitivity in Heroin Use Disorder Patients during Their Opioid Agonist Treatment
Abstract
:1. Introduction
1.1. Towards a Patient-Tailored Therapy in Opioid Use Disorder
1.2. Psychopathology Specific to Substance Use Disorder
1.3. Stress Sensitivity
1.3.1. SUD as a Risk Factor in Increasing Individual Susceptibility to PTSD
1.3.2. Assessment of PTSD Spectrum in HUD Patients: Developing an Instrument to Evaluate the PTSD Spectrum
2. Materials and Methods
2.1. Design of the Study
2.2. Sample
2.3. Instruments
- Drug Addiction History Questionnaire (DAH-Q) for the standard demographic and drug history data collection.
- Symptomatological Check List-90 (SCL-90) is a list of psychopathology symptoms.
- Heroin Craving Behavioural covariate (CRAV–HERO) is an inventory of heroin addictive behaviour.
- Heroin/PTSD-Spectrum questionnaire (H/PSTD-S), a new instrument developed to evaluate stress-sensitivity in HUD patients.
- Deltito Subjective Wellness Scale (D-SWS) is a self-report measure evaluating the quality of life.
- Cocaine Problem Severity Index (CPSI) is a questionnaire determining the extent of a cocaine problem.
- The Marijuana Craving Questionnaire (MC-Q) assesses the craving for cannabinoids.
2.3.1. Drug Addiction History Questionnaire (DAH-Q)
2.3.2. Symptomatological Check List-90 (SCL-90)
2.3.3. Heroin Craving Behavioural Covariate (CRAV-HERO)
2.3.4. Deltito Subjective Wellness Scale (D-SWS)
2.3.5. Cocaine Problem Severity Index (CPSI)
2.3.6. Marijuana Craving Questionnaire (MC-Q)
2.3.7. Stress Sensitivity—Heroin/PTSD-Spectrum (H/PTSD-S)
2.4. Data Analysis
3. Results
3.1. Demographic and Clinical Characteristics
3.2. Bivariate Correlation between the Severity of Stress Sensitivity, Length of Current Treatment, and Other Clinical Aspects
3.3. Differences between Patients with and without Heroin/Post-TrauPosttraumaticisorder—Spectrum (H/PTSD-S)
4. Discussion
4.1. Demographic and Clinical Characteristics
4.2. Bivariate Correlation between the Severity of Stress Sensitivity and Other Clinical Aspects
4.3. Differences between Patients with and without Heroin/Post-TrauPosttraumaticisorder—Spectrum (H/PTSD-S)
5. Clinical and Research Implications
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Nestler, E.J. Epigenetic mechanisms of drug addiction. Neuropharmacology 2014, 76 Pt B, 259–268. [Google Scholar] [CrossRef] [Green Version]
- Potenza, M.N.; Sofuoglu, M.; Carroll, K.M.; Rounsaville, B.J. Neuroscience of behavioral and pharmacological treatments for addictions. Neuron 2011, 69, 695–712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koob, G.F.; Volkow, N.D. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry 2016, 3, 760–773. [Google Scholar] [CrossRef] [PubMed]
- NIDA. Addiction and Health. Available online: https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/addiction-health (accessed on 16 October 2022).
- Koob, G.F. Neurobiology of Opioid Addiction: Opponent Process, Hyperkatifeia, and Negative Reinforcement. Biol. Psychiatry 2020, 87, 44–53. [Google Scholar] [CrossRef] [Green Version]
- Rosen, D.; Hunsaker, A.; Albert, S.M.; Cornelius, J.R.; Reynolds, C.F. Characteristics and consequences of heroin use among older adults in the United States: A review of the literature, treatment implications, and recommendations for further research. Addict. Behav. 2011, 36, 279–285. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maremmani, I.; Pacini, M.; Pani, P.P. On Behalf of the ‘Basics on Addiction Group’, Basics on Addiction: A training package for medical practitioners or psychiatrists who treat opioid dependence. Heroin Addict. Relat. Clin. Probl. 2011, 13, 5–40. [Google Scholar]
- Mattick, R.P.; Breen, C.; Kimber, J.; Davoli, M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2014, 2, CD002207. [Google Scholar] [CrossRef] [PubMed]
- Kalk, N.J. Harm reduction in opioid treatment: An established idea under threat. Addiction 2019, 114, 20–21. [Google Scholar] [CrossRef] [Green Version]
- Kapadia, S.N.; Griffin, J.L.; Waldman, J.; Ziebarth, N.R.; Schackman, B.R.; Behrends, C.N. A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: A Qualitative Study. J. Gen. Intern. Med. 2021, 36, 1898–1905. [Google Scholar] [CrossRef]
- American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders; DSM-5 Task Force; American Psychiatric Association: Washington, DC, USA, 2013. [Google Scholar]
- Kessler, R.C.; McGonagle, K.A.; Zhao, S.; Nelson, C.B.; Hughes, M.; Eshleman, S.; Wittchen, H.U.; Kendler, K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 1994, 51, 8–19. [Google Scholar] [CrossRef]
- Ross, J.; Teesson, M.; Darke, S.; Lynskey, M.; Ali, R.; Ritter, A.; Cooke, R. The characteristics of heroin users entering treatment: Findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005, 24, 411–418. [Google Scholar] [CrossRef]
- Franke, B.; Michelini, G.; Asherson, P.; Banaschewski, T.; Bilbow, A.; Buitelaar, J.K.; Cormand, B.; Faraone, S.V.; Ginsberg, Y.; Haavik, J.; et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur. Neuropsychopharmacol. 2018, 28, 1059–1088. [Google Scholar] [CrossRef] [PubMed]
- Ross, H.E.; Swinson, R.; Doumani, S.; Larkin, E.J. Diagnosing comorbidity in substance abusers: A comparison of the test-retest reliability of two interviews. Am. J. Drug Alcohol Abuse 1995, 21, 167–185. [Google Scholar] [CrossRef] [PubMed]
- Hiser, J.; Koenigs, M. The Multifaceted Role of the Ventromedial Prefrontal Cortex in Emotion, Decision Making, Social Cognition, and Psychopathology. Biol. Psychiatry 2018, 83, 638–647. [Google Scholar] [CrossRef]
- Smoller, J.W.; Andreassen, O.A.; Edenberg, H.J.; Faraone, S.V.; Glatt, S.J.; Kendler, K.S. Psychiatric genetics and the structure of psychopathology. Mol. Psychiatry 2019, 24, 409–420. [Google Scholar] [CrossRef] [PubMed]
- Eaton, N.R.; Rodriguez-Seijas, C.; Carragher, N.; Krueger, R.F. Transdiagnostic factors of psychopathology and substance use disorders: A review. Soc. Psychiatry Psychiatr. Epidemiol. 2015, 50, 171–182. [Google Scholar] [CrossRef]
- Pani, P.P.; Maremmani, I.; Trogu, E.; Gessa, G.L.; Ruiz, P.; Akiskal, H.S. Delineating the psychic structure of substance abuse and addictions: Should anxiety, mood and impulse-control dysregulation be included? J. Affect. Disord. 2010, 122, 185–197. [Google Scholar] [CrossRef]
- Maremmani, A.G.I.; Pani, P.P.; Rovai, L.; Bacciardi, S.; Maremmani, I. Toward the Identification of a Specific Psychopathology of Substance Use Disorders. Front. Psychiatry 2017, 8, 68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maremmani, A.G.; Rovai, L.; Pani, P.P.; Pacini, M.; Lamanna, F.; Rugani, F.; Schiavi, E.; Dell’osso, L.; Maremmani, I. Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann. Gen. Psychiatry 2011, 10, 17. [Google Scholar] [CrossRef] [Green Version]
- Maremmani, A.G.; Pani, P.P.; Trogu, E.; Vigna-Taglianti, F.; Mathis, F.; Diecidue, R.; Kirchmayer, U.; Amato, L.; Ghibaudi, J.; Camposeragna, A.; et al. The impact of psychopathological subtypes on retention rate of patients with substance use disorder entering residential therapeutic community treatment. Ann. Gen. Psychiatry 2016, 15, 29. [Google Scholar] [CrossRef] [Green Version]
- Derogatis, L.R.; Lipman, R.S.; Rickels, K.; Uhlenhuth, E.H.; Covi, L. The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav. Sci. 1974, 19, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Carpenter, K.M.; Hittner, J.B. Dimensional characteristics of the SCL-90-R: Evaluation of gender differences in dually diagnosed inpatients. J. Clin. Psychol. 1995, 51, 383–390. [Google Scholar] [CrossRef] [PubMed]
- Gerra, G.; Leonardi, C.; Cortese, E.; Zaimovic, A.; Dell’Agnello, G.; Manfredini, M.; Somaini, L.; Petracca, F.; Caretti, V.; Baroni, C.; et al. Adrenocorticotropic hormone and cortisol plasma levels directly correlate with childhood neglect and depression measures in addicted patients. Addict. Biol. 2008, 13, 95–104. [Google Scholar] [CrossRef] [PubMed]
- Zack, M.; Toneatto, T.; Streiner, D.L. The SCL-90 factor structure in comorbid substance abusers. J. Subst. Abuse 1998, 10, 85–101. [Google Scholar] [CrossRef]
- Pani, P.P.; Trogu, E.; Vigna-Taglianti, F.; Mathis, F.; Diecidue, R.; Kirchmayer, U.; Amato, L.; Davoli, M.; Ghibaudi, J.; Camposeragna, A.; et al. Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment. Ann. Gen. Psychiatry 2014, 13, 35. [Google Scholar] [CrossRef] [Green Version]
- Pani, P.P.; Maremmani, A.G.I.; Trogu, E.; Vigna-Taglianti, F.; Mathis, F.; Diecidue, R.; Kirchmayer, U.; Amato, L.; Davoli, M.; Ghibaudi, J.; et al. Psychic Structure of Opioid Addiction: Impact of Lifetime Psychiatric Problems on SCL-90-based Psychopathologic Dimensions in Heroin-dependent Patients. Addict. Disord. Their. Treat. 2016, 15, 6–16. [Google Scholar] [CrossRef]
- Pani, P.P.; Maremmani, A.G.I.; Trogu, E.; Vigna-Taglianti, F.; Mathis, F.; Diecidue, R.; Kirchmayer, U.; Amato, L.; Ghibaudi, J.; Camposeragna, A.; et al. Psychopathology of addiction: May a SCL-90 based five dimensions structure be applied irrespectively of the involved drug? Ann. Gen. Psychiatry 2016, 15, 13. [Google Scholar] [CrossRef] [Green Version]
- Carbone, M.G.; Maiello, M.; Spera, V.; Manni, C.; Pallucchini, A.; Maremmani, A.G.I.; Maremmani, I. The SCL90-based psychopathological structure may be applied in Substance Use Disorder patients irrespectively of the involved drug also in heroin, alcohol and cocaine mono-drug users. Heroin Addict. Relat. Clin. Probl. 2018, 20, 29–34. [Google Scholar]
- Maremmani, A.G.I.; Gazzarrini, D.; Fiorin, A.; Cingano, V.; Bellio, G.; Perugi, G.; Maremmani, I. Psychopathology of addiction: Is the SCL90-based five dimensional structure applicable to a non-substance-related addictive disorder such as Gambling Disorder? Ann. Gen. Psychiatry 2018, 17, 3. [Google Scholar] [CrossRef] [Green Version]
- Maremmani, A.G.I.; Maiello, M.; Carbone, M.G.; Pallucchini, A.; Brizi, F.; Belcari, I.; Conversano, C.; Perugi, G.; Maremmani, I. Towards a psychopathology specific to Substance Use Disorder: Should emotional responses to life events be included? Compr. Psychiatry 2018, 80, 132–139. [Google Scholar] [CrossRef] [PubMed]
- Carbone, M.G.; Tagliarini, C.; Ricci, M.; Lupi, A.M.; Sarandrea, L.; Ceban, A.; Casella, P.; Maremmani, I. Ethnicity and specific psychopathology of addiction. Comparison between migrant and Italian Heroin Use Disorder patients. Heroin Addict. Relat. Clin. Probl. 2019, 21, 61–66. [Google Scholar]
- Maremmani, A.G.I.; Lovrecic, M.; Lovrecic, B.; Maremmani, I. Ethnicity and specific psychopathology of addiction. Comparison between Slovenian and Italian Heroin Use Disorder patients. Heroin Addict. Relat. Clin. Probl. 2019, 21, 35–39. [Google Scholar]
- Maremmani, I.; Iantomasi, C.; Pani, P.P.; Maremmani, A.G.I.; Mathis, F. For the VOECT Group, A prospective study of psychopathology stability and changes after 3-month drug-abstinence in Italian Substance Use Disorder patients during a residential treatment. Heroin Addict. Relat. Clin. Probl. 2020, 22, 35–43. [Google Scholar]
- Maremmani, A.G.I.; Rovai, L.; Bacciardi, S.; Massimetti, E.; Gazzarrini, D.; Pallucchini, A.; Rugani, F.; Pani, P.P.; Maremmani, I. Psychopathological dimensions and addictive behaviours in Heroin Use Disorder patients. Heroin Addict. Relat. Clin. Probl. 2016, 18, 43–50. [Google Scholar]
- Della Rocca, F.; Maremmani, A.; Rovai, L.; Bacciardi, S.; Lamanna, F.; Maremmani, I. Further evidence of a specific psychopathology of Heroin Use Disorder. Relationships between psychopathological dimensions and addictive behaviors. Heroin Addict. Relat. Clin. Probl. 2017, 19, 13–20. [Google Scholar]
- Pagni, L.; Conversano, C.; Miccoli, M.; Maremmani, A.G.I.; Maremmani, I. Is the psychopathology specific of Substance Use Disorder able to differentiate problematic and non-problematic recreational drinkers? Heroin Addict. Relat. Clin. Probl. 2020, 22, 49–56. [Google Scholar]
- Miccoli, M.; Poli, A.; Pagni, L.; Conversano, C.; Pani, P.P.; Maremmani, A.G.I.; Maremmani, I. Further evidence of a psychopathology specific to Substance Use Disorder. Relationships between psychopathological dimensions and alcohol craving in recreational drinkers. Heroin Addict. Relat. Clin. Probl. 2021, 23, 69–77. [Google Scholar]
- Miccoli, M.; Della Rocca, F.; Maremmani, A.G.I.; Maremmani, I. Psychopathological syndromes and risk of alcoholism in Heroin Use Disorder patients compared with Substance-Non-Use peers. Heroin Addict. Relat. Clin. Probl. 2021, 23, 71–79. [Google Scholar]
- Maremmani, A.G.I.; Della Rocca, F.; Bacciardi, S.; Miccoli, M.; Maremmani, I. Convergent validity of five-dimension psychopathology of Addiction: Relationships with aggressive behaviour. Heroin Addict. Relat. Clin. Probl. 2021, 23, 75–80. [Google Scholar]
- Maremmani, A.G.I.; Della Rocca, F.; Bacciardi, S.; Miccoli, M.; Maremmani, I. Convergent validity of five-dimension psychopathology of Addiction: Relationships with Tridimensional Personality Questionnaire. Heroin Addict. Relat. Clin. Probl. 2021, 23, 59–64. [Google Scholar]
- Della Rocca, F.; Maremmani, A.G.I.; Bacciardi, S.; Miccoli, M.; Maremmani, I. Can the Psychopathology Specific to Substance Use Disorder Distinguish between Recreational Cocaine Use and Cocaine Addiction? Heroin Addict. Relat. Clin. Probl. 2022, 24, 43–50. [Google Scholar]
- Maremmani, A.G.I.; Cerniglia, L.; Cimino, S.; Bacciardi, S.; Rovai, L.; Rugani, F.; Massimetti, E.; Gazzarrini, D.; Pallucchini, A.; Pani, P.P.; et al. Towards a specific psychopathology of heroin addiction. Comparison between Heroin Use Disorder and Major Depression patients. Heroin Addict. Relat. Clin. Probl. 2015, 17, 9–16. [Google Scholar]
- Rugani, F.; Paganin, W.; Maremmani, A.G.I.; Perugi, G.; Maremmani, I. Towards a specific psychopathology of heroin addiction. Comparison between Heroin Use Disorder and Chronic Psychotic patients. Heroin Addict. Relat. Clin. Probl. 2019, 21, 53–59. [Google Scholar]
- Maremmani, A.G.I.; Pallucchini, A.; Manni, C.; Cipollone, G.; Della Rocca, F.; Salarpi, G.; Perugi, G.; Maremmani, I. Can the psychopathology specific to Substance Use Disorder distinguish between reward and relief craving? Heroin Addict. Relat. Clin. Probl. 2020, 22, 5–11. [Google Scholar]
- Maremmani, A.G.I.; Cerniglia, L.; Cimino, S.; Maiello, M.; Della Rocca, F.; Maremmani, I. The psychopathology specific to Substance Use Disorder is able to discriminate between young people with and without Problematic Internet Use. Heroin Addict. Relat. Clin. Probl. 2020, 22, 39–47. [Google Scholar]
- Maremmani, A.G.I.; Cerniglia, L.; Cimino, S.; Bacciardi, S.; Rovai, L.; Pallucchini, A.; Spera, V.; Perugi, G.; Maremmani, I. Further evidence of a specific psychopathology of addiction. Differentiation from other psychiatric psychopathological dimensions (such as obesity). Int. J. Environ. Res. Public Health 2017, 14, 943. [Google Scholar] [CrossRef] [Green Version]
- Baker, T.B.; Piper, M.E.; McCarthy, D.E.; Majeskie, M.R.; Fiore, M.C. Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychol. Rev. 2004, 111, 33–51. [Google Scholar] [CrossRef] [Green Version]
- Moos, R.H.; Finney, J.W.; Chan, D.A. The process of recovery from alcoholism. I. Comparing alcoholic patients and matched community controls. J. Stud. Alcohol. 1981, 42, 383–402. [Google Scholar] [CrossRef] [PubMed]
- Leventhal, H.; Cleary, P.D. The smoking problem: A review of the research and theory in behavioral risk modification. Psychol. Bull. 1980, 88, 370–405. [Google Scholar] [CrossRef] [PubMed]
- Chaplin, T.M.; Niehaus, C.; Goncalves, S.F. Stress reactivity and the developmental psychopathology of adolescent substance use. Neurobiol. Stress 2018, 9, 133–139. [Google Scholar] [CrossRef]
- Khantzian, E.J. An ego/self theory of substance dependence: A contemporary psychoanalitic perspective. NIDA Res. Monogr. 1980, 30, 29–33. [Google Scholar]
- Wills, T.A.; Hirky, A.E. Coping and substance abuse: A theoretical model and review of the evidence. In Handbook of Coping: Theory, Research, Applications; Zeidner, M., Endler, N.S., Eds.; John Wiley & Sons: Oxford, UK, 1966; pp. 279–302. [Google Scholar]
- Sinha, R. Chronic stress, drug use, and vulnerability to addiction. Ann. N. Y. Acad. Sci. 2008, 1141, 105–130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koob, G.F.; Buck, C.L.; Cohen, A.; Edwards, S.; Park, P.E.; Schlosburg, J.E.; Schmeichel, B.; Vendruscolo, L.F.; Wade, C.L.; Whitfield, T.W., Jr.; et al. Addiction as a stress surfeit disorder. Neuropharmacology 2014, 76 Pt B, 370–382. [Google Scholar] [CrossRef] [Green Version]
- Dell’Osso, L.; Rugani, F.; Maremmani, A.G.; Bertoni, S.; Pani, P.P.; Maremmani, I. Towards a unitary perspective between post-traumatic stress disorder and substance use disorder. Heroin use disorder as case study. Compr. Psychiatry 2014, 55, 1244–1251. [Google Scholar] [CrossRef] [PubMed]
- Cacciola, J.S.; Koppenhaver, J.M.; Alterman, A.I.; McKay, J.R. Post-traumatic stress disorder and other psychopathology in substance abusing patients. Drug Alcohol Depend. 2009, 101, 27–33. [Google Scholar] [CrossRef] [Green Version]
- Contoreggi, C.; Herning, R.I.; Na, P.; Gold, P.W.; Chrousos, G.; Negro, P.J.; Better, W.; Cadet, J.L. Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease. Biol. Psychiatry 2003, 54, 873–878. [Google Scholar] [CrossRef]
- Fosnocht, A.Q.; Briand, L.A. Substance use modulates stress reactivity: Behavioral and physiological outcomes. Physiol. Behav. 2016, 166, 32–42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goeders, N.E. The impact of stress on addiction. Eur. Neuropsychopharmacol. 2003, 13, 435–441. [Google Scholar] [CrossRef]
- Koob, G.; Kreek, M.J. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry 2007, 164, 1149–1159. [Google Scholar] [CrossRef] [Green Version]
- Kosten, T.R. Stress and addiction. Am. J. Psychiatry 2011, 168, 566–568. [Google Scholar] [CrossRef]
- McClintick, J.N.; Xuei, X.; Tischfield, J.A.; Goate, A.; Foroud, T.; Wetherill, L.; Ehringer, M.A.; Edenberg, H.J. Stress-response pathways are altered in the hippocampus of chronic alcoholics. Alcohol 2013, 47, 505–515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Preston, K.L.; Epstein, D.H. Stress in the daily lives of cocaine and heroin users: Relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology 2011, 218, 29–37. [Google Scholar] [CrossRef] [Green Version]
- Stewart, J. Pathways to relapse: The neurobiology of drug- and stress-induced relapse to drug-taking. J. Psychiatry Neurosci. 2000, 25, 125–136. [Google Scholar] [PubMed]
- Weiss, F.; Ciccocioppo, R.; Parsons, L.H.; Katner, S.; Liu, X.; Zorrilla, E.P.; Valdez, G.R.; Ben-Shahar, O.; Angeletti, S.; Richter, R.R. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann. N. Y. Acad. Sci. 2001, 937, 1–26. [Google Scholar] [CrossRef] [PubMed]
- Reynolds, M.; Mezey, G.; Chapman, M.; Wheeler, M.; Drummond, C.; Baldacchino, A. Comorbid post-traumatic stress disorder in a substance misusing clinical population. Drug Alcohol Depend. 2005, 77, 251–258. [Google Scholar] [CrossRef]
- Briand, L.A.; Blendy, J.A. Not all stress is equal: CREB is not necessary for restraint stress reinstatement of cocaine-conditioned reward. Behav. Brain Res. 2013, 246, 63–68. [Google Scholar] [CrossRef] [Green Version]
- Zorn, J.V.; Schur, R.R.; Boks, M.P.; Kahn, R.S.; Joels, M.; Vinkers, C.H. Cortisol stress reactivity across psychiatric disorders: A systematic review and meta-analysis. Psychoneuroendocrinology 2017, 77, 25–36. [Google Scholar] [CrossRef] [PubMed]
- Parrott, A.C.; Sands, H.R.; Jones, L.; Clow, A.; Evans, P.; Downey, L.A.; Stalder, T. Increased cortisol levels in hair of recent Ecstasy/MDMA users. Eur. Neuropsychopharmacol. 2014, 24, 369–374. [Google Scholar] [CrossRef] [PubMed]
- Xie, P.; Wang, T.J.; Yin, G.; Yan, Y.; Xiao, L.H.; Li, Q.; Bi, K.S. Metabonomic Study of Biochemical Changes in Human Hair of Heroin Abusers by Liquid Chromatography Coupled with Ion Trap-Time of Flight Mass Spectrometry. J. Mol. Neurosci. 2016, 58, 93–101. [Google Scholar] [CrossRef]
- Howard, D.E.; Debnam, K.J.; Wang, M.Q. Ten-year trends in physical dating violence victimisation among US adolescent females. J. Sch. Health 2013, 83, 389–399. [Google Scholar] [CrossRef]
- Kingston, S.; Raghavan, C. The relationship of sexual abuse, early initiation of substance use, and adolescent trauma to PTSD. J. Trauma. Stress 2009, 22, 65–68. [Google Scholar] [CrossRef] [PubMed]
- Macedo, T.; Ribeiro, C.A.; Cotrim, D.; Tavares, P.; Morgadinho, M.T.; Caramona, M.; Vicente, M.T.; Rodrigues, L.; Cardoso, M.G.; Keating, M.L. Catecholamine and MHPG plasma levels, platelet MAO activity, and 3H-imipramine binding in heroin and cocaine addicts. Mol. Neurobiol. 1995, 11, 21–29. [Google Scholar] [CrossRef] [PubMed]
- Gerra, G.; Zaimovic, A.; Zambelli, U.; Timpano, M.; Reali, N.; Bernasconi, S.; Brambilla, F. Neuroendocrine responses to psychological stress in adolescents with anxiety disorder. Neuropsychobiology 2000, 42, 82–92. [Google Scholar] [CrossRef] [PubMed]
- Gerra, G.; Somaini, L.; Manfredini, M.; Raggi, M.A.; Saracino, M.A.; Amore, M.; Leonardi, C.; Cortese, E.; Donnini, C. Dysregulated responses to emotions among abstinent heroin users: Correlation with childhood neglect and addiction severity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48, 220–228. [Google Scholar] [CrossRef]
- Parsons, L.H.; Smith, A.D.; Justice, J.B. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 1991, 9, 60–65. [Google Scholar] [CrossRef]
- Sher, L.; Vilens, A. Neurobiology of Post-Traumatic Stress Disorder; Nova Biomedical: New York, NY, USA, 2010; 376p. [Google Scholar]
- Drapkin, M.L.; Yusko, D.; Yasinski, C.; Oslin, D.; Hembree, E.A.; Foa, E.B. Baseline functioning among individuals with post-traumatic stress disorder and alcohol dependence. J. Subst. Abuse Treat. 2011, 41, 186–192. [Google Scholar] [CrossRef] [Green Version]
- Read, J.P.; Brown, P.J.; Kahler, C.W. Substance use and post-traumatic stress disorders: Symptom interplay and effects on outcome. Addict. Behav. 2004, 29, 1665–1672. [Google Scholar] [CrossRef]
- Mills, K.L.; Marel, C.; Darke, S.; Ross, J.; Slade, T.; Teesson, M. The long-term impact of post traumatic stress disorder on recovery from heroin dependence. J. Subst. Abuse Treat. 2018, 89, 60–66. [Google Scholar] [CrossRef]
- Malhi, G.S.; Boyce, P. A spectrum of views. Aust. N. Z. J. Psychiatry 2014, 48, 376–377. [Google Scholar] [CrossRef]
- Maremmani, I.; Miccoli, M. The TALS—Reduced form: An inventory for assessing the Heroin Post-Traumatic Stress Disorder Spectrum (H/PTSD-S). Heroin Addict. Relat. Clin. Probl. 2020, 22, 29–39. [Google Scholar]
- Maremmani, I.; Miccoli, M. An Inventory for Assessing the Heroin Post-Traumatic Stress Disorder Spectrum (H/PTSD-S); Addiction Research Methods Institute: Pisa, Italy, 2022. [Google Scholar]
- Dell’Osso, L.; Carmassi, C.; Rucci, P.; Conversano, C.; Shear, M.K.; Calugi, S.; Maser, J.D.; Endicott, J.; Fagiolini, A.; Cassano, G.B. A multidimensional spectrum approach to post-traumatic stress disorder: Comparison between the Structured Clinical Interview for Trauma and Loss Spectrum (SCI-TALS) and the Self-Report instrument (TALS-SR). Compr. Psychiatry 2009, 50, 485–490. [Google Scholar] [CrossRef]
- Dell’osso, L.; Shear, M.K.; Carmassi, C.; Rucci, P.; Maser, J.D.; Frank, E.; Endicott, J.; Lorettu, L.; Altamura, C.A.; Carpiniello, B.; et al. Validity and reliability of the Structured Clinical Interview for the Trauma and Loss Spectrum (SCI-TALS). Clin. Pract. Epidemiol. Ment. Health 2008, 4, 2. [Google Scholar] [CrossRef] [PubMed]
- Maremmani, I.; Cecchini, L.; Avella, M.T.; Novi, M.; Ciapparelli, A.; Maremmani, A.G.I. Prominent psychopathological and clinical characteristics of Heroin Post-Traumatic Stress Disorder Spectrum patients during treatment. Heroin Addict. Relat. Clin. Probl. 2020, 22, 37–48. [Google Scholar]
- Dole, V.P.; Nyswander, M.E. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrocloride. JAMA 1965, 193, 80–84. [Google Scholar] [CrossRef] [PubMed]
- Dole, V.P.; Nyswander, M.E.; Warner, A. Successful treatment of 750 criminal addicts. JAMA 1968, 206, 2708–2711. [Google Scholar] [CrossRef]
- Maremmani, I.; Castrogiovanni, P. DAH-Q: Drug Addiction History Questionnaire; University Press: Pisa, Italy, 1989. [Google Scholar]
- Maremmani, I.; Pani, P.P.; Pacini, M.; Bizzarri, J.V.; Trogu, E.; Maremmani, A.G.; Gerra, G.; Perugi, G.; Dell’Osso, L. Subtyping patients with heroin addiction at treatment entry: Factor derived from the Self-Report Symptom Inventory (SCL-90). Ann. Gen. Psychiatry 2010, 9, 15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maremmani, A.G.I.; Rovai, L.; Bacciardi, S.; Massimetti, E.; Gazzarrini, D.; Rugani, F.; Pallucchini, A.; Piz, L.; Maremmani, I. An inventory for assessing the behavioural covariates of craving in heroin substance use disorder. Development, theoretical description, reliability, exploratory factor analysis and preliminary construct validity. Heroin Addict. Relat. Clin. Probl. 2015, 17, 51–60. [Google Scholar]
- Rawson, R.A.; ObertJ, L.; McCann, D.P.; Smith, D.P.; Scheffey, E.H. The Neurobehavioural Treatment Manual: A Therapist Manual for Outpatient Cocaine Addiction Treatment; Matrix Center: Bevery Hills, CA, USA, 1989. [Google Scholar]
- Heishman, S.J.; Singleton, E.G.; Liguori, A. Marijuana Craving Questionnaire: Development and initial validation of a self-report instrument. Addiction 2001, 96, 1023–1034. [Google Scholar] [CrossRef]
- Tiffany, S.T.; Drobes, D.J. The development and initial validation of a questionnaire on smoking urges. Br. J. Addict. 1991, 86, 1467–1476. [Google Scholar] [CrossRef]
- Tiffany, S.T.; Singleton, E.; Haertzen, C.A.; Henningfield, J.E. The development of a cocaine craving questionnaire. Drug Alcohol Depend. 1993, 34, 19–28. [Google Scholar] [CrossRef]
- Dell’osso, L.; Carmassi, C.; Stratta, P.; Massimetti, G.; Akiskal, K.K.; Akiskal, H.S.; Maremmani, I.; Rossi, A. Gender Differences in the Relationship between Maladaptive Behaviors and Post-Traumatic Stress Disorder. A Study on 900 L’ Aquila 2009 Earthquake Survivors. Front. Psychiatry 2012, 3, 111. [Google Scholar] [CrossRef] [Green Version]
- McLellan, A.T.; McKay, J.R.; Forman, R.; Cacciola, J.; Kemp, J. Reconsidering the evaluation of addiction treatment: From retrospective follow-up to concurrent recovery monitoring. Addiction 2005, 100, 447–458. [Google Scholar] [CrossRef]
- Bell, J.; Strang, J. Medication Treatment of Opioid Use Disorder. Biol. Psychiatry 2020, 87, 82–88. [Google Scholar] [CrossRef]
- Maremmani, I.; Hill, D.; Sherbaum, N.; Auriacombe, M.; Bacciardi, S.; Benyamina, A.; Casella, P.; D’Agnone, O.; Daulouede, J.-P.; Deruvo, G.; et al. Early-readmission after Agonist Opioid Treatment in five European countries. A drug addiction health policy challenge? Heroin Addict. Relat. Clin. Probl. 2021, 23, 69–79. [Google Scholar]
- Newman, R.G. The Pharmacological Rationale for Methadone Treatment of Narcotic Addiction. In Drug Addiction and Related Clinical Problems; Tagliamonte, A., Maremmani, I., Eds.; Springer: Wien, Austria; New York, NY, USA, 1995; pp. 109–118. [Google Scholar]
- Bizzarri, I.V.; Casetti, V.; Sanna, L.; Maremmani, A.G.I.; Rovai, L.; Bacciardi, S.; Piacentino, D.; Conca, A.; Maremmani, I. Agonist Opioid Treatment as historical comprehensive treatment (‘Dole & Nyswander’ methodology) is associated with better toxicology outcome than Harm Reduction Treatment. Ann. Gen. Psychiatry 2016, 15, 34. [Google Scholar] [PubMed] [Green Version]
- Maremmani, A.G.I.; Pacini, M.; Pani, P.P.; Ceccanti, M.; Bacciardi, S.; Akiskal, H.S.; Maremmani, I. Possible trajectories of addictions: The role of bipolar spectrum. Heroin Addict. Relat. Clin. Probl. 2016, 18, 23–32. [Google Scholar]
- Maremmani, A.G.I.; Bacciardi, S.; Rovai, L.; Rugani, F.; Massimetti, E.; Gazzarrini, D.; Dell’Osso, L.; Maremmani, I. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: A retrospective study. Int. J. Environ. Res. Public Health 2014, 11, 12983. [Google Scholar] [CrossRef] [PubMed]
- Maremmani, A.G.I.; Bacciardi, S.; Rovai, L.; Rugani, F.; Dell’Osso, L.; Akiskal, H.S.; Maremmani, I. Do bipolar patients use street opioids to stabilise mood? Heroin Addict. Relat. Clin. Probl. 2013, 15, 25–32. [Google Scholar]
- Bacciardi, S.; Maremmani, A.G.I.; Rovai, L.; Rugani, F.; Pani, P.P.; Pacini, M.; Dell’Osso, L.; Akiskal, H.S.; Maremmani, I. Drug (heroin) addiction, bipolar spectrum and impulse control disorders. Heroin Addict. Relat. Clin. Probl. 2013, 15, 29–36. [Google Scholar]
- Maremmani, I.; Perugi, G.; Pacini, M.; Akiskal, H.S. Toward a Unitary Perspective on the Bipolar Spectrum and Substance Abuse: Opiate Addiction as a Paradigm. J. Affect. Disord. 2006, 93, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Maremmani, I.; Lamanna, F.; Pacini, M. Clinical Foundation for the Use of Methadone in Polyabuse Patients. In The Principles and Practice of Methadone Treatment; Maremmani, I., Ed.; Pacini Editore Medicina: Pisa, Italy, 2009; pp. 181–188. [Google Scholar]
- Maremmani, I.; Pacini, M. Use of Sodium Gamma-Hydroxybutyrate (GHB) in Alcoholic Heroin Addicts and Polydrug-Abusers. Heroin Addict. Relat. Clin. Probl. 2007, 9, 55–76. [Google Scholar]
- Bandettini Di Poggio, A.; Fornai, F.; Paparelli, A.; Pacini, M.; Perugi, G.; Maremmani, I. Comparison between heroin and heroin-cocaine polyabusers: A psychopathological study. Ann. N Y Acad. Sci. 2006, 1074, 438–445. [Google Scholar] [CrossRef]
- Maremmani, I.; Shinderman, M.S. Alcohol, benzodiazepines and other drugs use in heroin addicts treated with methadone. Polyabuse or undermedication? Heroin Addict. Relat. Clin. Probl. 1999, 1, 7–13. [Google Scholar]
- Maremmani, A.G.I.; Rovai, L.; Bacciardi, S.; Bertoni, S.; Massimetti, E.; Gazzarrini, D.; Rugani, F.; Pallucchini, A.; Maremmani, I. Addictive behaviours in Heroin Use Disorder patients. Correlation with heroin-craving patients’ self-evaluation. Heroin Addict. Relat. Clin. Probl. 2016, 18, 9–18. [Google Scholar]
- Geffen, D.B.; Blaustein, A.; Amir, M.C.; Cohen, Y. Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin’s disease and non-Hodgkin’s lymphoma in Israel. Leuk Lymphoma 2003, 44, 1925–1929. [Google Scholar] [CrossRef]
- Christiansen, D.M.; Berke, E.T. Gender- and Sex-Based Contributors to Sex Differences in PTSD. Curr. Psychiatry Rep. 2020, 22, 19. [Google Scholar] [CrossRef]
- Stalder, T.; Kirschbaum, C. Analysis of cortisol in hair—state of the art and future directions. Brain Behav. Immun. 2012, 26, 1019–1029. [Google Scholar] [CrossRef] [PubMed]
- Trevillion, K.; Oram, S.; Feder, G.; Howard, L.M. Experiences of domestic violence and mental disorders: A systematic review and meta-analysis. PLoS ONE 2012, 7, e51740. [Google Scholar] [CrossRef] [Green Version]
- Oram, S.; Trevillion, K.; Khalifeh, H.; Feder, G.; Howard, L.M. Systematic review and meta-analysis of psychiatric disorder and the perpetration of partner violence. Epidemiol. Psychiatr. Sci. 2014, 23, 361–376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Reekum, E.A.; Rosic, T.; Hudson, J.; Sanger, N.; Marsh, D.C.; Worster, A.; Thabane, L.; Samaan, Z. Social functioning outcomes in men and women receiving medication-assisted treatment for opioid use disorder. Biol. Sex Differ. 2020, 11, 20. [Google Scholar] [CrossRef] [PubMed]
- De Maeyer, J.; Vanderplasschen, W.; Camfield, L.; Vanheule, S.; Sabbe, B.; Broekaert, E. A good quality of life under the influence of methadone: A qualitative study among opiate-dependent individuals. Int. J. Nurs. Stud. 2011, 48, 1244–1257. [Google Scholar] [CrossRef] [PubMed]
- De Maeyer, J.; Vanderplasschen, W.; Broekaert, E. Quality of life among opiate-dependent individuals: A review of the literature. Int. J. Drug Policy 2010, 21, 364–380. [Google Scholar] [CrossRef] [PubMed]
- Feelemyer, J.P.; Jarlais, D.C.D.; Arasteh, K.; Phillips, B.W.; Hagan, H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review. Drug Alcohol Depend. 2014, 134, 251–258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Spearman’s Rho | Sig. (2-Tailed) | |
---|---|---|
Demographic data | ||
Income | 0.41 | 0.028 |
DAH-Q | ||
II. Mental Status areas altered | 0.46 | 0.005 |
III. Legal problems | 0.39 | 0.029 |
VIIa. Lifetime Different treatments | 0.35 | 0.041 |
VIIb. Current treatment load | 0.36 | 0.033 |
Psychopathology | 0.000 | |
SCL90 Global Score Index | 0.63 | 0.000 |
SCL90 Positive symptom Index | 0.60 | 0.002 |
SCL90 Positive symptom distress (severity) | 0.45 | 0.000 |
F1. Worthlessness/Being trapped | 0.58 | 0.000 |
F2. Somatic Symptoms | 0.60 | 0.000 |
F3. Sensitivity/Psychoticism | 0.57 | 0.000 |
F4. Panic/Anxiety | 0.49 | 0.000 |
F5. Violence/Suicide | 0.45 | 0.000 |
Deltito Wellness Scale | ||
Best week (last five years) contrast | −0.36 | 0.018 |
Stat | With H/PTSD-S N = 34 | Without H/PTSD-S N = 10 | |||
---|---|---|---|---|---|
Demographics | p | ||||
Female sex | N (%) | 11 (32.4%) | 0 (0.0%) | 0.046 | |
Income, poor | N (%) | 11 (32.4%) | 0 (0.0%) | 0.046 | |
DAH-Q | |||||
F3. Occupation, present | N (%) | 9 (26.5%) | 8 (80.0%) | 0.055 | |
F7. Legal problems, present | N (%) | 19 (55.9%) | 1 (10.0%) | 0.045 | |
U * | p | ||||
F2. Mental status areas altered | Median | 0.42 | 0.20 | 50.50 | 0.022 |
SCL-90 Data | |||||
SCL90 Global score index | Median | 1.22 | 0.40 | 52.00 | 0.001 |
SCL90 Positive symptom index | Median | 61.50 | 27.5 | 53.00 | 0.001 |
SCL90 Positive symptom distress (severity) | Median | 1.89 | 1.55 | 94.00 | 0.012 |
F1. Worthlessness/Being Trapped | Median | 1.66 | 0.47 | 65.00 | 0.002 |
F2. Somatic Symptoms | Median | 1.36 | 0.44 | 92.00 | 0.000 |
F3. Sensitivity/Psychoticism | Median | 0.94 | 0.20 | 69.00 | 0.004 |
F4. Panic Anxiety | Median | 0.66 | 0.05 | 72.00 | 0.005 |
F5. Violence/Suicide | Median | 1.25 | 0.50 | 81.00 | 0.012 |
DSWS Data | |||||
Poor week (last year) contrast | Median | 5.50 | 19.50 | 242.00 | 0.022 |
Best week (last five years) contrast | Median | 16.50 | 27.00 | 219.00 | 0.006 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Della Rocca, F.; Maremmani, A.G.I.; Bacciardi, S.; Pacini, M.; Lamanna, F.; Tripodi, B.; Miccoli, M.; Maremmani, I. Characteristics of Stress Sensitivity in Heroin Use Disorder Patients during Their Opioid Agonist Treatment. Int. J. Environ. Res. Public Health 2023, 20, 4566. https://doi.org/10.3390/ijerph20054566
Della Rocca F, Maremmani AGI, Bacciardi S, Pacini M, Lamanna F, Tripodi B, Miccoli M, Maremmani I. Characteristics of Stress Sensitivity in Heroin Use Disorder Patients during Their Opioid Agonist Treatment. International Journal of Environmental Research and Public Health. 2023; 20(5):4566. https://doi.org/10.3390/ijerph20054566
Chicago/Turabian StyleDella Rocca, Filippo, Angelo G. I. Maremmani, Silvia Bacciardi, Matteo Pacini, Francesco Lamanna, Beniamino Tripodi, Mario Miccoli, and Icro Maremmani. 2023. "Characteristics of Stress Sensitivity in Heroin Use Disorder Patients during Their Opioid Agonist Treatment" International Journal of Environmental Research and Public Health 20, no. 5: 4566. https://doi.org/10.3390/ijerph20054566